Myokardia (NASDAQ:MYOK) had its price objective increased by BMO Capital Markets from $65.00 to $83.00 in a report published on Friday. The firm currently has an outperform rating on the biotechnology company’s stock.
A number of other equities research analysts have also issued reports on the company. BidaskClub upgraded Myokardia from a hold rating to a buy rating in a research note on Saturday, February 17th. Zacks Investment Research lowered Myokardia from a hold rating to a sell rating in a research note on Wednesday, January 3rd. Credit Suisse Group reiterated an outperform rating and issued a $60.00 price target on shares of Myokardia in a research note on Thursday, January 18th. JPMorgan Chase & Co. started coverage on Myokardia in a research note on Tuesday, December 12th. They issued an overweight rating and a $54.00 price target for the company. Finally, ValuEngine upgraded Myokardia from a sell rating to a hold rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $63.00.
Shares of Myokardia (MYOK) opened at $53.05 on Friday. Myokardia has a 12 month low of $10.80 and a 12 month high of $62.83.
In other news, Director Kevin P. Starr sold 816,326 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total transaction of $34,285,692.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jake Bauer sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $42.89, for a total value of $214,450.00. Following the transaction, the insider now owns 62,877 shares of the company’s stock, valued at approximately $2,696,794.53. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 848,326 shares of company stock valued at $35,859,872. Company insiders own 33.40% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. grew its position in shares of Myokardia by 40.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 80,718 shares of the biotechnology company’s stock valued at $3,459,000 after purchasing an additional 23,172 shares in the last quarter. EAM Investors LLC bought a new position in shares of Myokardia in the 3rd quarter valued at about $4,216,000. Wells Fargo & Company MN lifted its holdings in shares of Myokardia by 2,151.7% in the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock valued at $17,887,000 after acquiring an additional 398,900 shares during the last quarter. Eversept Partners LLC bought a new position in shares of Myokardia in the 4th quarter valued at about $2,105,000. Finally, Northern Trust Corp lifted its holdings in shares of Myokardia by 31.9% in the 2nd quarter. Northern Trust Corp now owns 202,983 shares of the biotechnology company’s stock valued at $2,658,000 after acquiring an additional 49,044 shares during the last quarter. Hedge funds and other institutional investors own 83.91% of the company’s stock.
WARNING: This news story was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/03/12/myokardia-myok-price-target-increased-to-83-00-by-analysts-at-bmo-capital-markets.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.